Synergene Therapeutics
UEI: WY76BLRBNNN7
Overview
Awardee Type
Parent
(1 child)
Name
Synergene Therapeutics
Headquarters
Annapolis, MD
United States
United States
Most Recent Award
April 19, 2024
Calculating
Federal contract and grant recipient
SYNERGENE THERAPEUTICS INC
(UEI WY76BLRBNNN7)
is headquartered in Annapolis MD.
Its primary registered NAICS is 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The corporation
was founded in February 1998 and
federally registered in
August 2005.
Federal Award Analysis
Synergene Therapeutics federal award history
$-
Contracts
$-
Subcontracts
$-
Grants
$-
Subgrants
$-
Total
No Results
Calculating
Calculating
No Results
Calculating
Calculating
No Results
Calculating
Calculating
| Year | Contracts | Subcontracts | Grants | Subgrants |
|---|
No Results
Calculating
Calculating
No Results
Calculating
Calculating
Federal Registration and Certifications
This Parent entity does not have an associated active registration. Showing registration information for UEI W8E3G5851JK4 CAGE 43DC1 instead.
Legal Name
SYNERGENE THERAPEUTICS INC
UEI
W8E3G5851JK4
CAGE Code
43DC1
Primary NAICS
SBA Certifications
None
Self Certifications
For Profit Organization
Entity Structure
Corporate Entity (Not Tax Exempt)
Purpose of Registration
Federal Contracts and Assistance
Date Founded
Feb. 13, 1998
Initial Registration
Aug. 16, 2005
Last Registration
May 29, 2025
Registration Activation
May 29, 2025
Registration Expiration
May 27, 2026
Fiscal Year End
December 31
Reported Entity Types
For Profit Organization
State of Incorporation
DE
Country of Incorporation
USA
Employees
<500
Disaster Registry
Specific Regions
Reported NAICS
Accepts Credit Cards
No
People
Vendor contacts at Synergene Therapeutics
Contract Awards
Synergene Therapeutics prime contract awards
Grant Awards
Synergene Therapeutics direct grants
Subgrant Awards
Synergene Therapeutics subgrant awards
Teaming Partners
Disclosed awardee sub and prime contract and grant relationships
Synergene Therapeutics